Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDGFRB | P09619 | 1/20 | 0.50 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.50 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.50 |
| ▸ | FLT1 | P17948 | 1/20 | 0.50 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.50 |
| ▸ | KDR | P35968 | 1/20 | 0.50 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.44 |
| ▸ | VCAM1 | P19320 | 1/20 | 0.42 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.42 |
| ▸ | ITGA5 | P08648 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
| ▸ | ESPL1 | Q14674 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | GALR2 | O43603 | 1/20 | 0.40 |
| ▸ | MITF | O75030 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1560111 | 0.93 | PDGFRB (0.47) | PDGFRBFGFR1PDGFRAFLT1FGFR3 | |
| SCHEMBL32659715 | 0.92 | PDGFRB (0.51) | PDGFRBFGFR1PDGFRAFLT1FGFR3 | |
| SCHEMBL2895340 | 0.90 | PDGFRB (0.50) | PDGFRBFGFR1PDGFRAFLT1FGFR3 | |
| SCHEMBL12164843 | 0.87 | PDGFRB (0.55) | PDGFRBFGFR1PDGFRAFLT1FGFR3 | |
| SCHEMBL21801654 | 0.87 | PDGFRB (0.48) | PDGFRBFGFR1PDGFRAFLT1FGFR3 | |
| SCHEMBL471041 | 0.87 | PDGFRB (0.62) | PDGFRBFGFR1PDGFRAFLT1FGFR3 | |
| SCHEMBL31575920 | 0.87 | PDGFRB (0.48) | PDGFRBFGFR1PDGFRAFLT1FGFR3 | |
| SCHEMBL1785458 | 0.86 | MEN1 (0.48) | PDGFRBFGFR1PDGFRAFLT1FGFR3 | |
| SCHEMBL6474988 | 0.86 | PDGFRB (0.47) | PDGFRBFGFR1PDGFRAFLT1FGFR3 | |
| SCHEMBL3336950 | 0.86 | TDP1 (0.47) | PDGFRBFGFR1PDGFRAFLT1FGFR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 260 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116348115-B | Combination of antibody-drug conjugate and PARP1 selective inhibitor | ASTRAZENECA UK LTD. (GB) | 2026-05-26 | — | — | CN | disclosed |
| US-12606555-B2 | Chemical compounds | ASTRAZENECA AB (SE) | 2026-04-21 | — | — | US | disclosed |
| US-12454524-B2 | (r)-n-(4-(chlorodifluoromethoxy)phenyl)-2-(difluoromethyl)-1-(1-hydroxypropan-2-yl)-7-(pyrimidin-5-yl)-1H-benzo[d]imidazole-5-carboxamide, or a pharmaceutically acceptable salt or tautomer thereof, for treating certain leukemias | TERNS PHARMACEUTICALS, INC. (US) | 2025-10-28 | — | — | US | disclosed |
| US-20250276961-A1 | COMPOUNDS FOR TREATING CERTAIN LEUKEMIAS | Terns, Inc. | 2025-09-04 | — | — | US | disclosed |
| US-12384780-B2 | PARP1 inhibitors and uses thereof | XINTHERA, INC. (US) | 2025-08-12 | — | — | US | disclosed |
| US-20250243184-A1 | COMPOUNDS FOR TREATING CERTAIN LEUKEMIAS | Terns, Inc. | 2025-07-31 | — | — | US | disclosed |
| CN-120081844-A | PARP1 inhibitors and uses thereof | 新特拉有限公司 | 2025-06-03 | — | — | CN | disclosed |
| CN-115448908-B | Compounds for the treatment of specific leukemias | 拓臻股份有限公司 | 2025-04-25 | — | — | CN | disclosed |
| CN-119859155-A | Tri-fused ring derivative inhibitor, preparation method and application thereof | 江苏豪森药业集团有限公司 | 2025-04-22 | — | — | CN | disclosed |
| CN-115215838-B | Compounds for the treatment of specific leukemias | 拓臻股份有限公司 | 2025-04-04 | — | — | CN | disclosed |
| US-20080287479-A1 | INHIBITORS OF SERINE PALMITOYLTRANSFERASE | PFIZER INC | 2008-11-20 | — | — | US | disclosed |
| US-20080207635-A1 | Heterocyclic compounds useful in the treatment of neoplastic diseases, inflammatory disorders and immunomodulatory disorders | CHEMBRIDGE CORPORATION | 2008-08-28 | — | — | US | disclosed |
| US-20080207635-A1 | Heterocyclic compounds useful in the treatment of neoplastic diseases, inflammatory disorders and immunomodulatory disorders | CHEMBRIDGE CORPORATION | 2008-08-28 | — | — | US | disclosed |
| WO-2008084300-A1 | INHIBITORS OF SERINE PALMITOYLTRANSFERASE | PFIZER PRODUCTS INC. (US) | 2008-07-17 | — | — | WO | disclosed |
| WO-2008084300-A1 | INHIBITORS OF SERINE PALMITOYLTRANSFERASE | PFIZER PRODUCTS INC. (US) | 2008-07-17 | — | — | WO | disclosed |
| WO-2007019674-A1 | VIRAL POLYMERASE INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-02-22 | — | — | WO | disclosed |
| US-6972287-B1 | Method of inhibiting amyloid protein aggregation and imaging amyloid deposits | PFIZER INC. (US) | 2005-12-06 | — | — | US | disclosed |
| US-20040220235-A1 | Method of inhibiting amyloid protein aggregation and imaging amyloid deposits | AUGELLI-SZAFRAN CORINNE ELIZAB (US) | 2004-11-04 | — | — | US | disclosed |
| EP-1225886-A2 | METHOD OF INHIBITING AMYLOID PROTEIN AGGREGATION AND IMAGING AMYLOID DEPOSITS | WARNER-LAMBERT COMPANY (US) | 2002-07-31 | — | — | EP | disclosed |
| WO-2000076489-A2 | METHOD OF INHIBITING AMYLOID PROTEIN AGGREGATION AND IMAGING AMYLOID DEPOSITS | WARNER-LAMBERT COMPANY (US) | 2000-12-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12384780-B2 | PARP1 inhibitors and uses thereof | PARP1, PARP11, PARP12 | PDGFRB 412/4885FGFR1 3478/4885PDGFRA 646/4885 |
| US-20080287479-A1 | INHIBITORS OF SERINE PALMITOYLTRANSFERASE | SPTLC1, SPTLC2, CPT1A | PDGFRB 3832/4885FGFR1 4578/4885PDGFRA 4390/4885 |
| US-20250276961-A1 | COMPOUNDS FOR TREATING CERTAIN LEUKEMIAS | ABL1, ABL2, BCR | PDGFRB 592/4885FGFR1 768/4885PDGFRA 416/4885 |
| US-20250243184-A1 | COMPOUNDS FOR TREATING CERTAIN LEUKEMIAS | ABL1, ABL2, BCR | PDGFRB 592/4885FGFR1 768/4885PDGFRA 416/4885 |
| US-12606555-B2 | Chemical compounds | PARP1, PARP11, PARP12 | PDGFRB 586/4885FGFR1 3142/4885PDGFRA 581/4885 |
| US-12454524-B2 | (r)-n-(4-(chlorodifluoromethoxy)phenyl)-2-(difluoromethyl)-1-(1-hydroxypropan-2-yl)-7-(pyrimidin-5-yl)-1H-benzo[d]imidazole-5-carboxamide, or a pharmaceutically acceptable salt or tautomer thereof, for treating certain leukemias | ABL1, ABL2, BCR | PDGFRB 648/4885FGFR1 86/4885PDGFRA 226/4885 |
| US-20080207635-A1 | Heterocyclic compounds useful in the treatment of neoplastic diseases, inflammatory disorders and immunomodulatory disorders | LCK, MALT1, MYD88 | PDGFRB 685/4885FGFR1 632/4885PDGFRA 652/4885 |
| US-20040220235-A1 | Method of inhibiting amyloid protein aggregation and imaging amyloid deposits | APP, PSEN1, BACE1 | PDGFRB 4333/4885FGFR1 4698/4885PDGFRA 4475/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.